Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. The company was founded in 2019 and is based in Toronto, Canada.
Stock data | 2024 | Change |
---|---|---|
Price | $0.010438050172227828 | N/A |
Market Cap | $1.43M | N/A |
Shares Outstanding | 137.44M | N/A |
Employees | 0 | N/A |